22:03 , Jan 6, 2017 |  BC Week In Review  |  Company News

Amorsa, J&J deal

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson partnered with Amorsa to develop therapies for treatment-resistant depression. The partners will use the biotech's ketamine analog technology, and Janssen will hold options to developed programs....
00:57 , Jan 6, 2017 |  BC Extra  |  Company News

J&J reveals spate of partnerships

The Johnson & Johnson Innovation unit of Johnson & Johnson (NYSE:JNJ) unveiled a series of new partnerships Thursday, including collaborations in cancer, immunotherapy, and non-alcoholic steatohepatitis (NASH). Among the 15 deals, J&J's Janssen Pharmaceuticals unit...